Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

{{::item.ticker}} • {{::item.company_name}} No Results

Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

News & Research
Portfolio
Discover
Groups
$MCK {{ '2017-12-18T14:33:36+0000' | timeago}} • Announcement

$MCK said James Beer, EVP and CFO, will be leaving the company to pursue a new opportunity. Britt Vitalone, SVP and CFO, U.S. Pharmaceutical and McKesson Specialty Health, will be appointed EVP and CFO of McKesson, effective Jan. 1, 2018. Beer will assist in a transition period into early 2018.

$MCK {{ '2018-01-03T15:10:09+0000' | timeago}} • Announcement

$MCK announced that it has completed the acquisition of RxCrossroads.

$MCK {{ '2017-12-18T14:35:21+0000' | timeago}} • Announcement

$MCK CFO James Beer will be leaving the company. Britt Vitalone will be appointed EVP and CFO of the company, effective Jan. 1, 2018. In addition, $MCK reaffirmed its adjusted EPS outlook of $11.80-12.50 for FY18.

$MCK {{ '2017-12-18T14:33:36+0000' | timeago}} • Announcement

$MCK said James Beer, EVP and CFO, will be leaving the company to pursue a new opportunity. Britt Vitalone, SVP and CFO, U.S. Pharmaceutical and McKesson Specialty Health, will be appointed EVP and CFO of McKesson, effective Jan. 1, 2018. Beer will assist in a transition period into early 2018.

$MCK {{ '2017-11-17T18:06:55+0000' | timeago}} • Infographic

$MCK McKesson Corporation Earnings AlphaGraphic: Q2 2018 highlights

$MCK {{ '2017-10-11T18:31:37+0000' | timeago}} • Announcement

Biologics, a $MCK Specialty Health oncology pharmacy services company, has been selected by $LLY to be in the limited distribution network for Verzenio (abemaciclib), $LLY's first oral oncolytic indicated for metastatic breast cancer. Verzenio obstructs growth of cancer cells by specifically blocking cyclin-dependent kinases, CDK4 and CDK6.

$MCK {{ '2017-10-04T13:44:29+0000' | timeago}} • Announcement

McKesson Ventures, a unit of $MCK, has appointed Carrie Hurwitz as Principal. In addition, the company named Irem Mertol its Director. Most recently, Williams served as VP of Strategy and Business Development at Omada Health. Mertol comes to McKesson from Burd Health, where she held various leadership positions.

$MDRX {{ '2017-08-03T20:38:50+0000' | timeago}} • Announcement

Healthcare technology provider $MDRX has agreed to acquire the enterprise information solutions business of $MCK for $185MM in cash. The transaction is expected to close early in the fourth quarter of calendar year 2017. The company plans to fund the transaction through its existing secured credit facilities and cash balances.

$MCK {{ '2017-07-26T17:19:04+0000' | timeago}} • Announcement

$MCK said all board members were re-elected at the annual stockholders’ meeting. Also, all board vote recommendations were upheld, except the advisory vote on executive compensation. The Compensation Committee will review of the current executive compensation plan and consider implementing changes so as to align incentives and shareholder value.

$MCK {{ '2017-07-21T16:07:44+0000' | timeago}} • Announcement

Biologics, a unit of healthcare technology firm $MCK, said it will join the limited distribution network of $PBYI to promote the latter’s kinase inhibitor Nerlynx. The formulation is indicated for treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer.

$MCK {{ '2017-05-24T20:45:05+0000' | timeago}} • Announcement

The Board of Directors of $MCK declared a regular dividend of $0.28 per share on common stock. The dividend will be payable on July 3, 2017, to stockholders of record on June 5, 2017.

$MCK {{ '2017-05-18T22:30:24+0000' | timeago}} • Webcast

$MCK stated that on the buy side for generics, the company is seeing a deflation going forward. However, the company added that deflation is not a big factor that plays into the way its economics or P&L operates.

$MCK {{ '2017-05-18T21:05:10+0000' | timeago}} • Announcement

During 4Q17, $MCK's Distribution Solution revenues rose 5% YoY to $48.2Bil. Revenues of North America pharmaceutical distribution and services revenues were $40.6Bil, up 5%. International pharmaceutical distribution and services revenues were $6.1Bil and Medical-Surgical distribution and services revenues were $1.6Bil.

$MCK {{ '2017-05-18T21:01:30+0000' | timeago}} • Announcement

$MCK reported an increase in 4Q17 profit, due to a pre-tax gain of $3.9Bil related to the previously announced creation of the Change Healthcare joint venture. Net income rose to $3.6Bil, or $16.95 per share, compared to $431MM, or $1.97 per share during 4Q16. Revenues rose 4% YoY to $46.7Bil during the quarter.

$MCK {{ '2017-04-04T14:57:34+0000' | timeago}} • Announcement

$MCK completed the previously announced acquisition of CoverMyMeds LLC. CoverMyMeds is a player in electronic prior authorization (ePA) solutions.

$MCK {{ '2017-03-02T17:03:35+0000' | timeago}} • Announcement

$MCK lifted FY17 EPS from continuing operations guidance to $20.35-22.50 from $9.80-10.30, while lowering adjusted EPS outlook to $12.45-12.75 from $12.60-12.90. $MCK will record its share of a one-time, non-cash reduction to the carrying value of its deferred revenue balance. This will lower earnings in FY18 by about $140-170MM.

$MCK {{ '2017-03-02T16:59:04+0000' | timeago}} • Announcement

In 4Q17, $MCK expects to record a pre-tax gain of about $2.9-3.5Bil, which includes $1.25Bil in cash receipts, and associated non-cash income tax expense of about $0.5-0.8Bil, both of which will be excluded from adjusted earnings. As a result of net gain, $MCK will add about $10.70-12.35 in EPS from continuing operations.

$MCK {{ '2017-01-26T11:50:05+0000' | timeago}} • Announcement

$MCK's BoD declared a regular dividend of 28 cents per share on common stock. The dividend will be payable on April 3, 2017, to stockholders of record on March 1, 2017.

$MCK {{ '2017-01-25T23:00:05+0000' | timeago}} • Announcement

On Jan. 24, 2017 $MCK entered into an agreement to acquire CoverMyMeds for approx. $1.1Bil, or $0.9Bil net of incremental cash tax benefits. The transaction is subject to customary closing conditions, including regulatory review, and is expected to close in the first half of FY18.

$MCK {{ '2017-01-25T22:57:39+0000' | timeago}} • Announcement

During 3Q17, $MCK's Distribution Solutions reported 5% growth in its revenues to $49.4MM. North America pharmaceutical distribution and services revenues rose 5% to $41.7Bil and International pharmaceutical distribution and services revenues were $6.2Bil for the quarter, up 3%.

$MCK {{ '2017-01-25T22:53:51+0000' | timeago}} • Announcement

$MCK reported flat 3Q17 earnings results. Net income during the quarter was $633MM compared to $634 during 3Q16. Diluted EPS rose 4.3% YoverY to $2.85 from $2.73 due to the lower weighted average common share. Revenues rose 5% YoverY to $50.1Bil. Excluding items, $MCK earned $3.05 per share.

Recent Transcripts
NUS | Earnings
February 15th 2018, 10:00pm
ZTS | Earnings
February 15th 2018, 1:30pm
CSCO | Earnings
February 14th 2018, 9:31pm
ELMD | Earnings
February 14th 2018, 2:00pm
AlphaGraphics you may like
Related Feed
Recent Transcripts
NUS | Earnings
February 15th 2018, 10:00pm
ZTS | Earnings
February 15th 2018, 1:30pm
CSCO | Earnings
February 14th 2018, 9:31pm
ELMD | Earnings
February 14th 2018, 2:00pm
AlphaGraphics you may like